Literature DB >> 25844674

Metastatic carcinoma of unknown primary: diagnostic approach using immunohistochemistry.

James R Conner1, Jason L Hornick.   

Abstract

Carcinoma of unknown primary origin (CUP) is one of the 10 most prevalent malignancies. CUP patients in whom a site of origin can be ascribed have better outcomes than those in which the primary tumor remains unidentified. Among the tools available to pathologists in approaching these lesions, immunohistochemistry is a reliable, inexpensive, and widely available resource. New markers continue to emerge, which, in combination with other historically useful antibodies, allow rapid and accurate identification of primary site in an increasing number of cases. This review discusses the approach to the diagnosis of CUP using immunohistochemistry and outlines some of the most useful markers with a particular focus on the utility of lineage-restricted transcription factors, including CDX2, NKX3-1, PAX8, SATB2, TTF-1, and SF1.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25844674     DOI: 10.1097/PAP.0000000000000069

Source DB:  PubMed          Journal:  Adv Anat Pathol        ISSN: 1072-4109            Impact factor:   3.875


  27 in total

1.  'Inflammatory breast cancer' due to metastatic adenocarcinoma of lung.

Authors:  Jacob Ninan; Vinay Naik; Gemy Maria George
Journal:  BMJ Case Rep       Date:  2016-09-01

2.  Combination of GATA3, SOX-10, and PAX8 in a Comprehensive Panel to Diagnose Breast Cancer Metastases.

Authors:  Kiyong Na; Ha Young Woo; Sung-Im DO; So-Woon Kim
Journal:  In Vivo       Date:  2022 Jan-Feb       Impact factor: 2.155

3.  Sclerosing Signet Ring Cell Carcinoma of the Lacrimal Gland: A Potentially New Primary Entity.

Authors:  Frederick A Jakobiec; Edith R Reshef; Lina Ma; Martin K Selig; Daniel R Lefebvre; Anna M Stagner
Journal:  Ocul Oncol Pathol       Date:  2020-02-07

4.  NKX3-1 Is a Useful Immunohistochemical Marker of EWSR1-NFATC2 Sarcoma and Mesenchymal Chondrosarcoma.

Authors:  Ken-Ichi Yoshida; Isidro Machado; Toru Motoi; Antonina Parafioriti; Maribel Lacambra; Hitoshi Ichikawa; Akira Kawai; Cristina R Antonescu; Akihiko Yoshida
Journal:  Am J Surg Pathol       Date:  2020-06       Impact factor: 6.394

Review 5.  Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary.

Authors:  Sebastián Moran; Anna Martinez-Cardús; Stergios Boussios; Manel Esteller
Journal:  Nat Rev Clin Oncol       Date:  2017-07-04       Impact factor: 66.675

6.  SEOM clinical guideline on unknown primary cancer (2017).

Authors:  F Losa; G Soler; A Casado; A Estival; I Fernández; S Giménez; F Longo; R Pazo-Cid; J Salgado; M Á Seguí
Journal:  Clin Transl Oncol       Date:  2017-12-11       Impact factor: 3.405

7.  Putative lung adenocarcinoma with epidermal growth factor receptor mutation presenting as carcinoma of unknown primary site: A case report.

Authors:  Masahiro Yamasaki; Kunihiko Funaishi; Naomi Saito; Ayaka Sakano; Megumu Fujihara; Wakako Daido; Sayaka Ishiyama; Naoko Deguchi; Masaya Taniwaki; Nobuyuki Ohashi; Noboru Hattori
Journal:  Medicine (Baltimore)       Date:  2018-02       Impact factor: 1.817

Review 8.  Novel uses of immunohistochemistry in breast pathology: interpretation and pitfalls.

Authors:  Ashley Cimino-Mathews
Journal:  Mod Pathol       Date:  2020-10-27       Impact factor: 7.842

9.  Heterochronous Metastases of Lung Adenocarcinoma to Pancreas and Liver: A Case Report from Pathological Perspectives.

Authors:  Bo Zhang; Qida Hu; Jiajie Yu; Junsen Wang; Hanjin Yang; Jiongbo Lou; Guoying Cai; Haifeng Huang; Mengqiu Xu; Zhaoying Xiao; Yun Zhang
Journal:  Onco Targets Ther       Date:  2021-07-22       Impact factor: 4.147

10.  Triple malignancy in a single patient including a squamous cell carcinoma of the cervix, a colloid adenocarcinoma of the colon and a lung adenocarcinoma: A case report and literature review.

Authors:  Tarik Mahfoud; Rachid Tanz; Réda M Khmamouche; Massine M El Hammoumi; Mohamed Allaoui; Rhizlane Belbaraka; Mohamed Ichou
Journal:  Int J Surg Case Rep       Date:  2017-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.